Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

173
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
173
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

200
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
200
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

215
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
215
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.

Health technology assessment (Winchester, England)·2026
Same author

Development and Validation of Salivary Exosomal Tri-RNA Liquid Biopsy in Esophageal Carcinoma: A Multicenter Study.

JCO precision oncology·2026
Same author

Correction: Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Scientific reports·2026
Same author

Isolation of postnatal human neural stem cells.

bioRxiv : the preprint server for biology·2026
Same author

Esophageal Innominate Artery Fistula after Delayed Recognition of Esophageal Foreign Body.

Ear, nose, & throat journal·2026
Same author

Polyclonal regeneration of mouse bone marrow endothelial cells after irradiative conditioning.

Cell reports·2026

Related Experiment Video

Updated: May 28, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.3K

Using cimetidine to mitigate cisplatin-induced ototoxicity.

Rahul Sinha1, Si Ja Liu2, Rebekah Lee2

  • 1Department of Otolaryngology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, United States of America.

Toxicology in Vitro : an International Journal Published in Association with BIBRA
|February 13, 2025
PubMed
Summary

Cimetidine may prevent cisplatin-induced hearing loss by blocking the organic cation transporter 2 (OCT2) in ear cells. This approach could reduce ototoxicity without compromising cisplatin's anti-cancer efficacy.

Keywords:
CimetidineCisplatinHouse ear institute-organ of Corti 1 (HEI-OC1) cellsOtotoxicity

More Related Videos

Dissection of Adult Mouse Utricle and Adenovirus-mediated Supporting-cell Infection
11:13

Dissection of Adult Mouse Utricle and Adenovirus-mediated Supporting-cell Infection

Published on: March 28, 2012

23.7K
Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
09:06

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice

Published on: January 9, 2019

13.8K

Related Experiment Videos

Last Updated: May 28, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.3K
Dissection of Adult Mouse Utricle and Adenovirus-mediated Supporting-cell Infection
11:13

Dissection of Adult Mouse Utricle and Adenovirus-mediated Supporting-cell Infection

Published on: March 28, 2012

23.7K
Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
09:06

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice

Published on: January 9, 2019

13.8K

Area of Science:

  • Ototoxicity research
  • Pharmacology
  • Cancer therapeutics

Background:

  • Cisplatin is a vital chemotherapy drug, but its use is limited by ototoxicity (inner ear damage).
  • Organic cation transporter 2 (OCT2) facilitates cisplatin entry into inner ear cells, contributing to ototoxicity.
  • Cimetidine is an FDA-approved drug known to inhibit OCT2 activity.

Purpose of the Study:

  • To investigate if cimetidine can prevent cisplatin-induced ototoxicity by inhibiting OCT2.
  • To assess if this protective effect impacts cisplatin's efficacy against cancer cells.

Main Methods:

  • Utilized House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line to model inner ear cells.
  • Assessed cell viability after exposure to cisplatin and cimetidine.
  • Evaluated the combined effect of cisplatin and cimetidine on cancer cell lines.

Main Results:

  • Cisplatin reduced HEI-OC1 cell viability in a dose-dependent manner.
  • Cimetidine counteracted cisplatin-induced ototoxicity in HEI-OC1 cells.
  • Cimetidine did not interfere with cisplatin's cytotoxic effects on cancer cells.

Conclusions:

  • Inhibiting OCT2 with cimetidine shows promise in mitigating cisplatin-induced ototoxicity.
  • Combined therapy may offer a strategy to reduce hearing loss in cancer patients undergoing cisplatin treatment.
  • This approach could improve the therapeutic index of cisplatin chemotherapy.